Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens

British Journal of Haematology

Volumn 162, Issue 3, 2013, Pages 376-382

  Chellapandian, Deepakbabu ^a   Das, Rupali ^b   Zelley, Kristin ^b   Wiener, Susan J ^b   Zhao, Huaqing ^b   Teachey, David T ^b   Nichols, Kim E ^b  

^a EINSTEIN MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Epstein Barr virus; Haemophagocytic lymphohistiocytosis; Macrophage activation syndrome; Rituximab; X linked lymphoproliferative disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CYCLOSPORIN A; ETOPOSIDE; FERRITIN; IMMUNOGLOBULIN; RITUXIMAB; STEROID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CHILL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFECT; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FACIAL SWELLING; FEMALE; FERRITIN BLOOD LEVEL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; IMMUNOGLOBULIN DEFICIENCY; IMMUNOTHERAPY; MALE; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SWELLING; TACHYCARDIA; THROMBOCYTE COUNT; URTICARIA; VIRUS LOAD;

EPSTEIN-BARR VIRUS; HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; MACROPHAGE ACTIVATION SYNDROME; RITUXIMAB; X-LINKED LYMPHOPROLIFERATIVE DISEASE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; DRUG THERAPY, COMBINATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84880319443     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12386     Document Type: Article

References (34)

1. Aksoy, S., Harputluoglu, H., Kilickap, S., Dede, D.S., Dizdar, O., Altundag, K. & Barista, I. (2007) Rituximab-related viral infections in lymphoma patients. Leukaemia & Lymphoma, 48, 1307-1312.
2. Allen, C.E., Yu, X., Kozinetz, C.A. & McClain, K.L. (2008) Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer, 50, 1227-1235.
3. Beutel, K., Gross-Wieltsch, U., Wiesel, T., Stadt, U.Z., Janka, G. & Wagner, H.J. (2009) Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin. Pediatric Blood & Cancer, 53, 184-190.
4. Booth, C., Gilmour, K.C., Veys, P., Gennery, A.R., Slatter, M.A., Chapel, H., Heath, P.T., Steward, C.G., Smith, O., O'Meara, A., Kerrigan, H., Mahlaoui, N., Cavazzana-Calvo, M., Fischer, A., Moshous, D., Blanche, S., Pachlopnik Schmid, J., Latour, S., de Saint-Basile, G., Albert, M., Notheis, G., Rieber, N., Strahm, B., Ritterbusch, H., Lankester, A., Hartwig, N.G., Meyts, I., Plebani, A., Soresina, A., Finocchi, A., Pignata, C., Cirillo, E., Bonanomi, S., Peters, C., Kalwak, K., Pasic, S., Sedlacek, P., Jazbec, J., Kanegane, H., Nichols, K.E., Hanson, I.C., Kapoor, N., Haddad, E., Cowan, M., Choo, S., Smart, J., Arkwright, P.D. & Gaspar, H.B. (2011) X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood, 117, 53-62.
5. Coffey, A.J., Brooksbank, R.A., Brandau, O., Oohashi, T., Howell, G.R., Bye, J.M., Cahn, A.P., Durham, J., Heath, P., Wray, P., Pavitt, R., Wilkinson, J., Leversha, M., Huckle, E., Shaw-Smith, C.J., Dunham, A., Rhodes, S., Schuster, V., Porta, G., Yin, L., Serafini, P., Sylla, B., Zollo, M., Franco, B., Bolino, A., Seri, M., Lanyi, A., Davis, J.R., Webster, D., Harris, A., Lenoir, G., De St Basile, G., Jones, A., Behloradsky, B.H., Achatz, H., Murken, J., Fassler, R., Sumegi, J., Romeo, G., Vaudin, M., Ross, M.T., Meindl, A. & Bentley, D.R. (1998) Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nature Genetics, 20, 129-135.
6. Cote, M., Menager, M.M., Burgess, A., Mahlaoui, N., Picard, C., Schaffner, C., Al-Manjomi, F., Al-Harbi, M., Alangari, A., Le Deist, F., Gennery, A.R., Prince, N., Cariou, A., Nitschke, P., Blank, U., El-Ghazali, G., Menasche, G., Latour, S., Fischer, A. & de Saint Basile, G. (2009) Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. The Journal of Clinical Investigation, 119, 3765-3773.
7. DiNardo, C.D. & Tsai, D.E. (2010) Treatment advances in posttransplant lymphoproliferative disease. Current Opinion in Hematology, 17, 368-374.
8. Feldmann, J., Callebaut, I., Raposo, G., Certain, S., Bacq, D., Dumont, C., Lambert, N., Ouachee-Chardin, M., Chedeville, G., Tamary, H., Minard-Colin, V., Vilmer, E., Blanche, S., Le Deist, F., Fischer, A. & de Saint Basile, G. (2003) Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell, 115, 461-473.
9. Henter, J.I., Horne, A., Arico, M., Egeler, R.M., Filipovich, A.H., Imashuku, S., Ladisch, S., McClain, K., Webb, D., Winiarski, J. & Janka, G. (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer, 48, 124-131.
10. Imashuku, S. (2002) Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Critical Reviews in Oncology Hematology, 44, 259-272.
11. Imashuku, S. (2011) Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010. Journal of Pediatric Hematology/oncology, 33, 35-39.
12. Janka, G.E. (2012) Familial and acquired hemophagocytic lymphohistiocytosis. Annual Review of Medicine, 63, 233-246.
13. Kawaguchi, H., Miyashita, T., Herbst, H., Niedobitek, G., Asada, M., Tsuchida, M., Hanada, R., Kinoshita, A., Sakurai, M. & Kobayashi, N. (1993) Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. The Journal of Clinical Investigation, 92, 1444-1450.
14. Kimby, E. (2005) Tolerability and safety of rituximab (MabThera). Cancer Treatment Reviews, 31, 456-473.
15. Lin, T.F., Ferlic-Stark, L.L., Allen, C.E., Kozinetz, C.A. & McClain, K.L. (2011) Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatric Blood & Cancer, 56, 154-155.
16. Lykens, J.E., Terrell, C.E., Zoller, E.E., Risma, K. & Jordan, M.B. (2011) Perforin is a critical physiologic regulator of T-cell activation. Blood, 118, 618-626.
17. Maloney, D.G. (2012) Anti-CD20 antibody therapy for B-cell lymphomas. New England Journal of Medicine, 366, 2008-2016.
18. McClain, K., Gehrz, R., Grierson, H., Purtilo, D. & Filipovich, A. (1988) Virus-associated histiocytic proliferations in children. Frequent association with Epstein-Barr virus and congenital or acquired immunodeficiencies. The American Journal of Pediatric Hematology/Oncology, 10, 196-205.
19. Meeths, M., Entesarian, M., Al-Herz, W., Chiang, S.C., Wood, S.M., Al-Ateeqi, W., Almazan, F., Boelens, J.J., Hasle, H., Ifversen, M., Lund, B., Van Den Berg, J.M., Gustafsson, B., Hjelmqvist, H., Nordenskjold, M., Bryceson, Y.T. & Henter, J.I. (2010) Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood, 116, 2635-2643.
20. Nichols, K.E., Harkin, D.P., Levitz, S., Krainer, M., Kolquist, K.A., Genovese, C., Bernard, A., Ferguson, M., Zuo, L., Snyder, E., Buckler, A.J., Wise, C., Ashley, J., Lovett, M., Valentine, M.B., Look, A.T., Gerald, W., Housman, D.E. & Haber, D.A. (1998) Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proceedings of the National Academy of Sciences of the United States of America, 95, 13765-13770.
21. Pachlopnik Schmid, J., Canioni, D., Moshous, D., Touzot, F., Mahlaoui, N., Hauck, F., Kanegane, H., Lopez-Granados, E., Mejstrikova, E., Pellier, I., Galicier, L., Galambrun, C., Barlogis, V., Bordigoni, P., Fourmaintraux, A., Hamidou, M., Dabadie, A., Le Deist, F., Haerynck, F., Ouachee-Chardin, M., Rohrlich, P., Stephan, J.L., Lenoir, C., Rigaud, S., Lambert, N., Milili, M., Schiff, C., Chapel, H., Picard, C., de Saint Basile, G., Blanche, S., Fischer, A. & Latour, S. (2011) Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood, 117, 1522-1529.
22. Pasic, S., Micic, D. & Kuzmanovic, M. (2003) Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis in Wiskott-Aldrich syndrome. Acta Paediatrica, 92, 859-861.
23. Qin, Q., Xie, Z., Shen, Y., Yang, S., Liu, C., Huang, Z., Xu, J., Al, J. & Shen, K. (2012) Assessment of immunochemotherapy and stem cell transplantation on EBV-associated hemophagocytic lymphohistiocytosis in children: a systematic review and meta analysis. European Review for Medical and Pharmacological Sciences., 16, 672-678.
24. Rezaei, N., Hedayat, M., Aghamohammadi, A. & Nichols, K.E. (2011) Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. The Journal of Allergy and Clinical Immunology, 127, 1329-1341. e1322; quiz 1342-1323.
25. Rigaud, S., Fondaneche, M.C., Lambert, N., Pasquier, B., Mateo, V., Soulas, P., Galicier, L., Le Deist, F., Rieux-Laucat, F., Revy, P., Fischer, A., de Saint Basile, G. & Latour, S. (2006) XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature, 444, 110-114.
26. Risma, K. & Jordan, M.B. (2012) Hemophagocytic lymphohistiocytosis: updates and evolving concepts. Current Opinion in Pediatrics, 24, 9-15.
27. Shiraishi, A., Ohga, S., Doi, T., Ishimura, M., Takimoto, T., Takada, H., Miyamoto, T., Abe, Y. & Hara, T. (2012) Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer, 59, 265-270.
28. Stepp, S.E., Dufourcq-Lagelouse, R., Le Deist, F., Bhawan, S., Certain, S., Mathew, P.A., Henter, J.I., Bennett, M., Fischer, A., de Saint Basile, G. & Kumar, V. (1999) Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science, 286, 1957-1959.
29. Teramura, T., Tabata, Y., Yagi, T., Morimoto, A., Hibi, S. & Imashuku, S. (2002) Quantitative analysis of cell-free Epstein-Barr virus genome copy number in patients with EBV-associated hemophagocytic lymphohistiocytosis. Leukaemia & Lymphoma, 43, 173-179.
30. Wolach, O., Bairey, O. & Lahav, M. (2010) Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine, 89, 308-318.
31. Yachie, A., Kanegane, H. & Kasahara, Y. (2003) Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative diseases. Seminars in Hematology, 40, 124-132.
32. Yang, X., Wada, T., Imadome, K., Nishida, N., Mukai, T., Fujiwara, M., Kawashima, H., Kato, F., Fujiwara, S., Yachie, A., Zhao, X., Miyawaki, T. & Kanegane, H. (2012) Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2. Herpesviridae, 3, 1.
33. Zur Stadt, U., Schmidt, S., Kasper, B., Beutel, K., Diler, A.S., Henter, J.I., Kabisch, H., Schneppenheim, R., Nurnberg, P., Janka, G. & Hennies, H.C. (2005) Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Human Molecular Genetics, 14, 827-834.
34. Zur Stadt, U., Rohr, J., Seifert, W., Koch, F., Grieve, S., Pagel, J., Strauss, J., Kasper, B., Nurnberg, G., Becker, C., Maul-Pavicic, A., Beutel, K., Janka, G., Griffiths, G., Ehl, S. & Hennies, H.C. (2009) Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. American Journal of Human Genetics, 85, 482-492.